Securities code: 603716 securities abbreviation: Thalys Medical Technology Group Corporation(603716) Announcement No.: 2022-006
Bond Code: 113601 bond abbreviation: Saili convertible bond
Thalys Medical Technology Group Corporation(603716)
Announcement on signing major contracts for daily operation by wholly-owned subsidiaries of the company
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
Important content tips:
1. Thalys Medical Technology Group Corporation(603716) (hereinafter referred to as ” Thalys Medical Technology Group Corporation(603716) ” or “company”)
Wuhan SELIS Biotechnology Co., Ltd. (hereinafter referred to as “SELIS biotechnology”), a wholly-owned subsidiary of the company
The sales partner agreement was signed with ate gold kuyumculuk on January 20, 2022
Discussion (hereinafter referred to as “covid-19 test kit sales contract”), the first phase of ate gold kuyumculuk
Purchase covid-19 test kit of US $20 million from biotechnology, and order it for the first trial
The amount of the order is US $1 million. At present, the other party has paid a deposit of US $100000.
2. The total amount of this order is US $20 million, of which US $1 million is a confirmed order, and the rest is
There is a risk that the other party will not continue to purchase in the order of 19 million US dollars. If the other party confirms that it will not purchase in the future, it will not
Shall bear any liability for breach of contract. The above contract shall come into force on January 20, 2022 and shall be valid for 12 months
Months, the contract can be automatically renewed for 12 months upon expiration. The contract is completed by stages, and the specific delivery time has not been determined yet
It is clear that there may be a risk of long sales time or inability to sell.
Special risk tips:
1. Risk of successful performance of the transaction contract: the Turkish company will be based on the epidemic development and market sales
Confirm whether to continue purchasing covid-19 test reagent with the remaining amount of USD 19 million from biotechnology
Box. Virus mutation, vaccination and the introduction of covid-19 drugs all have an impact on the development of the epidemic
Therefore, the development of epidemic situation in the future has strong uncertainty, which may have a significant impact
Implementation of the product contract of the kit;
2. The impact of this order on the company’s performance is uncertain: the above contract will be signed in January 2022
The contract is valid for 12 months and can be automatically renewed for 12 months upon expiration. There may be a risk of long sales time or inability to sell. The performance of the covid-19 reagent kit sales contract is expected to have great uncertainty about the company’s financial status and operating results.
3. Market competition pressure and order continuity risk: at present, the company has no other overseas orders except the above orders. Other manufacturers in China have obtained EU CE certification. This product license is not unique to the company. At present, the competition in the EU market is fierce, and there is uncertainty whether the company will continue to obtain relevant orders in the future; The covid-19 test kit produced by the company has not obtained the medical device registration certificate issued by the State Drug Administration of China, and cannot be sold in the Chinese market.
4. Risk of revenue decline: the contract amount signed this time is CIF price, including transportation expenses. Recently, international freight fluctuates greatly, and there may be a risk of contract revenue decline due to the increase of transportation expenses.
5. Supply risk: due to the epidemic situation, there is a shortage of transportation capacity in air, sea and other transportation modes at present. If the epidemic situation in China changes or other force majeure factors lead to the decline of the supply capacity of raw materials for biotechnology production and the closure of production facilities, it will lead to the decline of biotechnology production capacity, which may lead to biotechnology breach of contract, If the contract is not executed, biotechnology shall also bear relevant losses.
Please make prudent decisions and rationally judge investment risks.
1、 Contract signing
Cyrus biotechnology and ate gold kuyumculuk signed the first phase of the covid-19 test kit sales contract on January 20, 2022. Cyrus biotechnology sold covid-19 test kits to ate gold kuyumculuk. In the first phase, it set the total order amount of USD 20 million in two batches as the purchase pool. According to the exchange rate of USD to RMB 1 = 6.3427 yuan when the contract is signed on January 20, 2022
The total amount is about RMB 126854000. The contract price of the first phase of covid-19 test kit trial sales order is US $1 million (including freight). If the contract is successfully performed within this year, the expected net profit will exceed 50% of the company’s audited non net profit in 2020, but there is a risk that the other party will not continue to purchase the remaining US $19 million orders, If the other party subsequently confirms that it will not continue to purchase, it will have no significant impact on the financial status and operating results of the current year.
The above contract belongs to the daily business scope of Thales biotechnology and has been signed and entered into force on January 20, 2022. The above contract does not need to be deliberated and approved by the board of directors and the general meeting of shareholders.
(I) subject matter of the contract
In the first stage, the total order amount of USD 20 million is set as the purchase pool in two batches. The first batch of trial sales orders will be delivered in the first batch, with a total amount of US $1 million.
(II) contract counterparty (the contract counterparty is a Turkish enterprise)
1. Enterprise Name: ate gold kuyumculuk San TC Ltd st
Nature of enterprise: lmted
Place of registration: bnbrdrek mah Peykhane sok. Kamer i han no:16,taksim/fatih/STANBUL
Date of establishment: October 19, 2020
Main office: bnbrdrek mah Peykhane sok. Kamer i han no:16,taksim/fatih/STANBUL
Legal representative: Gokhan ates
Registered capital: 500.000 lira
Main business: Beyazit
Major shareholder or actual controller: ghkan ates
2. The other party of the contract is mainly engaged in trade businesses such as science and technology, timber, building materials and medicine. It is in good development and has good performance conditions.
3. There is no affiliated relationship or other interest arrangement between the contract counterparty and the company and its holding subsidiaries.
4. The counterparty of the contract has no business dealings with the company and its holding subsidiaries in recent three fiscal years.
5. Main financial data of contract counterparties in the last year
Unit: USD 10000
December 31, 2020
Total assets 22567.55
Net assets 1638.59
Operating income 38241.73
Net profit 425.65
3、 Main terms of the contract
Counterparty: ate gold kuyumculuk
Main contents of the contract
1. Contract signing time and effective date: January 20, 2022
2. Contract object: sars-cov-2 (covid 19) IgM / IgG antibody rapid detection kit (colloidal gold) and sars-cov-2 (covid 19) IgM / IgG antigen rapid detection kit (colloidal gold) (hereinafter referred to as “covid-19 detection kit”).
3. Contract amount: in the first stage, the total order amount is set as USD 20 million in two batches as the purchase pool. The contract price of the first trial sales order including tax is US $1 million (including freight). According to the exchange rate of US $1 to RMB = 6.3427 yuan when the contract is signed on January 20, 2022, the total contract amount is about RMB 126854000.
4. Performance period: it shall be completed in stages from January 20, 2022, and shall continue to be fully effective for 12 months, and shall be automatically renewed for 12 consecutive months, unless terminated by either party after 60 days’ prior written notice.
5. Payment method: 10% of the total amount shall be paid as a deposit; 20% when the goods are delivered to the agent; 30% after the goods arrive at the port; The remaining 40% shall be paid after customs clearance.
6. Liability for breach of contract: Thales biotechnology shall bear limited liability for any suspected defective products sold under the warranty terms attached to the products.
4、 Explain the impact of contract performance on listed companies
(I) Cyrus biotechnology and ate gold kuyumculuk signed the first phase of the sales contract of covid-19 test kit on January 20, 2022. Cyrus biotechnology sold covid-19 test kit to ate gold kuyumculuk. In the first phase, it set the total order amount of USD 20 million in two batches as the purchase pool. The total amount of the first trial sales shipment is US $1 million.
The performance of covid-19 test kit sales contract will have a positive impact on the operating revenue and operating profit of the listed company in 2022. The listed company will recognize the revenue during the corresponding accounting year according to the performance of the contract and the revenue recognition principle. The relevant financial data are indeed subject to the audited financial report.
At present, Thales biotechnology has three production lines, which can meet the needs of business orders.
(II) the performance of the above contracts does not affect the business independence of the listed company, and the company’s main business will not change due to the performance of the above contracts, but the above contracts find a new profit growth point for the company. 5、 Risk analysis of contract performance
During the execution of the contract, it may be affected by the local covid-19 epidemic situation in Turkey, the update of epidemic detection technology, the adjustment capacity of biotechnology supply chain, policy changes, logistics and distribution risks, the supply of upstream production raw materials and other force majeure factors, There may be risks that the contract cannot be performed on schedule or in full (see “special risk tips” in the “major tips” of the announcement for details).
Please make prudent decisions and rationally judge investment risks.
The company will disclose the performance progress of the contract in accordance with relevant laws and regulations.
6、 Documents for future reference
1. Sales partner agreement (phase I)
2. Communication email between Thales biotechnology and ate gold kuyumculuk
It is hereby announced.
Thalys Medical Technology Group Corporation(603716) board of directors January 21, 2022
